BPC 157
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence studied for tissue-healing and cyto-protective properties. Preclinical models demonstrate accelerated wound repair and anti-inflammatory activity, though human clinical data remain limited to early-phase safety trials and small case reports. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.
Reconstitution Steps
Draw 2.0 mL bacteriostatic water with a sterile syringe. EACH
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Protocol Overview
Concise summary of the once-daily regimen based on clinical trial designs.
Goal: Support tissue repair, reduce inflammation, and accelerate recovery from musculoskeletal injuries.
Schedule: TB-500 twice weekly (loading) then once weekly (maintenance); BPC-157 daily throughout.
Dose Range: TB-500: 1,250 mcg per injection; BPC-157: 250–500 mcg daily.
Reconstitution: 2.0 mL per 5 mg vial for both peptides (~2.5 mg/mL).
Storage: Refrigerate lyophilized and reconstituted solutions; use within ~30 days after reconstitution.
Dosing Protocol
Suggested daily titration approach reflecting clinical study parameters.
TB-500 Loading: 1,250 mcg twice weekly for 4 weeks (total ~2.5 mg/week).
TB-500 Maintenance: 1,250 mcg once weekly for Weeks 5–12.
BPC-157 Start: 250 mcg daily for 2 weeks, then increase to 500 mcg daily.
BPC-157 Taper: Return to 250 mcg daily for final 4 weeks (Weeks 9–12).
Timing: Inject at consistent times; BPC-157 preferably near injury site.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at 2–8 °C (35.6–46.4 °F); for long-term storage, −20 °C (−4 °F) is acceptable.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~30 days; avoid freeze–thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) for TB-500; inject BPC-157 near the target tissue when possible.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose, injection site, and any observations to maintain consistency.
Both peptides may be administered on the same day but at different injection sites.
How This Works
TB-500 mimics endogenous thymosin β4, modulating inflammation and activating repair pathways including PI3K/Akt and Notch signaling to enhance angiogenesis and cell migration. It promotes actin sequestration and is studied for accelerating wound healing, reducing fibrosis, and improving function after ischemic or traumatic injuries.
BPC-157 upregulates angiogenic pathways (including VEGF) and counteracts inflammatory cytokines. Preclinical research demonstrates improved healing of muscle, tendon, ligament, and bone with no observed toxicity. The combination targets complementary mechanisms: TB-500 for systemic tissue repair signaling and BPC-157 for localized healing support.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
TB-500: Preclinical studies show accelerated wound closure, reduced fibrosis, and improved function after ischemic or traumatic injuries.
BPC-157: Preclinical models demonstrate accelerated recovery of tendon, ligament, muscle, and bone injuries with no observed toxicity. One clinical series found pain relief in 7 of 12 patients after a single intraarticular knee injection.
Stack Rationale: The combination may offer complementary mechanisms—systemic repair signaling (TB-500) plus localized tissue healing (BPC-157).
Side Effects: Generally well tolerated in research settings; occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.
Lifestyle Factors
Complementary strategies that may support therapeutic goals.
Pair with a balanced, protein-adequate diet to support muscle synthesis and recovery.
Combine resistance training and cardiovascular exercise to maximize anabolic and metabolic benefits.
Prioritize 7–9 hours of quality sleep nightly, as GH naturally peaks during deep sleep phases.
Manage stress levels, as chronic stress and elevated cortisol can blunt GH response.
Inject on an empty stomach (avoid food 2–3 hours before and 30–60 minutes after) to optimize GH release.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
Clean your hands and work on a clean surface.
Swab the vial’s rubber stopper and injection site with alcohol; allow to dry.
Draw the calculated dose into the insulin syringe, eliminating air bubbles.
Suitable SC injection areas include the abdomen (2 inches from navel), outer thighs, upper outer arms, or flank/hip area.
Pinch a fold of skin between thumb and forefinger; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
After injection, release the pinched skin and withdraw the needle at the same angle.
Apply gentle pressure with a clean cotton or alcohol pad; do not rub vigorously.
Rotate sites systematically with each dose to prevent irritation or tissue damage.
Immediately dispose of the used syringe in a proper sharps container.
